IP Library Granted Patent US 10,612,002
Granted Patent B2
US 10,612,002 · App. 15/437,786 · Granted Apr 7, 2020

Human pluripotent stem cell derived endocardial endothelium

Inventors: Charles E. Murry (Seattle, WA); Lil Pabon (Seattle, WA); Nathan Palpant (Seattle, WA)
Assignee: UNIVERSITY OF WASHINGTON
C12N5/0657A61K35/545C12N2501/115C12N2501/155C12N2501/16C12N2501/165
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,612,002
App. No.
15/437,786
Granted
Apr 7, 2020
Kind
B2
Abstract

Provided herein are methods that enable the polarization of hPSC mesoderm such that closely related yet distinct cardiovascular populations can be generated efficiently without the need of post-facto enrichment.

Claims (12)

1. A method for generating human endocardial endothelial cells, comprising:

(i) culturing adherent human pluripotent stem cells in defined medium comprising B27 and at least 100 ng/mL Activin A in the absence of insulin for 12-20 hours,

(ii) culturing the cells of step (i) in defined medium in the absence of insulin, in the presence of Bone Morphogenetic Protein 4 (BMP4) in a concentration that is less than 30 ng/mL, and CHIR-99021 for 20-28 hours,

(iii) culturing the cells of step (ii) in defined medium in the absence of Wnt inhibitor, comprising vascular endothelial growth factor (VEGF), BMP-4 and bFGF for 3 days or until NFATc1 expression is detectable,

thereby generating human endocardial endothelial cells.

2. The method of claim 1 , wherein the pluripotent stem cells comprise human embryonic stem cells (ESCs) or human induced pluripotent stem cells (iPSCs).

3. The method of claim 1 , wherein the BMP4 is present in defined medium at a concentration less than 10 ng/mL.

4. The method of claim 1 , which generates a culture comprising at least 60% endocardial endothelial cells, without the need for a cell sorting or enrichment step.

5. The method of claim 4 , wherein the endocardial endothelial cells are NFATc1+.

6. The method of claim 1 , wherein less than 1% of the resulting cells are CD43 + and CD235a + .

7. The method of claim 1 , wherein the concentration of BMP4 is selected from the group consisting of: 1-30 ng/mL, 5-30 ng/mL, 5-20 ng/mL, 10-30 ng/mL, or 10-20 ng/mL.

8. The method of claim 1 , wherein the concentration of Activin A is selected from the group consisting of: at least 105 ng/mL, at least 110 ng/mL, at least 120 ng/mL or at least 150 ng/mL.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 8, 2018
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046102/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2017
From: MURRY, CHARLES E.; PABON, LIL; PALPANT, NATHAN
To: UNIVERSITY OF WASHINGTON
Reel/Frame 042238/0426 →
Continuity (2)
Provisional Application 62297241 · Feb 19, 2016
Related Publication 20170240861A1 · Aug 24, 2017